Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker.
about
Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: a systematic reviewGene polymorphisms predict toxicity to neoadjuvant therapy in patients with rectal cancerSerum VEGFR-3 and survival of advanced gastric cancer patients treated with FOLFOX.Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 yearsThymidylate synthase genotype-directed chemotherapy for patients with gastric and gastroesophageal junction cancersDNA polymerase η protein expression predicts treatment response and survival of metastatic gastric adenocarcinoma patients treated with oxaliplatin-based chemotherapyERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis.ERCC1 and ERCC2 variants predict survival in gastric cancer patients.XRCC1 and XPD genetic polymorphisms and clinical outcomes of gastric cancer patients treated with oxaliplatin-based chemotherapy: a meta-analysis.Association between the ERCC1 rs11615 polymorphism and clinical outcomes of oxaliplatin-based chemotherapies in gastrointestinal cancer: a meta-analysisTranslational medicine and reliability of single-nucleotide polymorphism studies: can we believe in SNP reports or not?Platinum-induced neurotoxicity and preventive strategies: past, present, and futureInformative gene network for chemotherapy-induced peripheral neuropathyPolymorphisms of ERCC1 and XRCC1 predict the overall survival of advanced gastric cancer patients receiving oxaliplatin-based chemotherapy.The Efficacy of Taxanes- and Oxaliplatin-Based Chemotherapy in the Treatment of Gastric Cancer After D2 Gastrectomy for Different Lauren Types.A phase II study of a modified FOLFOX6 regimen as neoadjuvant chemotherapy for locally advanced gastric cancer.ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer.Association between polymorphisms in XRCC1 gene and treatment outcomes of patients with advanced gastric cancer: a systematic review and meta-analysis.Gastric cancer pharmacogenetics: progress or old tripe?X-ray repair cross-complementing 1 polymorphism and prognosis of platinum-based chemotherapy in gastric and colorectal cancer: a meta-analysis.North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma.Predictive value of GSTP1 Ile105Val polymorphism in clinical outcomes of chemotherapy in gastric and colorectal cancers: a systematic review and meta-analysis.A phase II trial of modified FOLFOX6 as first-line therapy for adenocarcinoma of an unknown primary site.Polymorphisms of GSTP1, ERCC2 and TS-3'UTR are associated with the clinical outcome of mFOLFOX6 in colorectal cancer patients.A functional polymorphism of SSBP1 gene predicts prognosis and response to chemotherapy in resected gastric cancer patients.Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies.Effects of modified FOLFOX-6 chemotherapy on cellular immune function in patients with gastric cancer.
P2860
Q26824719-2C8531F2-6525-44AE-B722-C5D20B80DFFBQ28392548-13EBA455-1771-4C4A-9D1E-45C831DBA89BQ33830752-114079AC-7464-4685-854C-34F4F32B9C92Q34008793-3BB03982-EB57-4965-9427-CA16767CAC27Q34214957-48D3DA63-DC86-45C9-AC74-0AFE4D6B2119Q34413771-1BCE2A8F-37CB-40AC-A671-D0E61A594300Q34694410-0F3AB50C-0F61-423A-A4F9-D9E871EF88CEQ34983863-C87F07A7-A6F4-4E2A-8035-EE5AAF65BF74Q35109749-30F1A864-A16C-4C57-9899-974C3B91EC5CQ35194655-AC6E12E2-0E3F-418C-B6E0-A260B6AF6686Q35196724-EC4B6743-7F6C-4443-A3E6-9012A6B041F0Q35345734-A16AAE4C-A264-498E-81AC-4808EA59BC23Q35945680-BAD1C55A-AE20-4F82-9C95-6B07D56AB875Q36411838-2887C285-241D-4C8F-80AE-372F06DAA815Q36581129-B8BB2B2C-A6DF-4CC5-B476-3563F06C6906Q37174037-DCA064B4-5B5D-4D62-965A-DF6085D0E3BBQ37397021-FC45773C-2AF6-4E69-AC17-7D2BFC0556EEQ37499473-BC216EB3-7DAF-43A1-BFBD-15F58F1D7D94Q38120288-6990B7B9-058E-40C1-B1F8-CD15BFF7C8D5Q38162285-147EFE98-DFBD-4C71-B41B-112466880915Q38792393-FD8B9663-2ADE-4D9A-9D7A-2426446862AAQ38827826-933D47D5-D294-468F-A9FB-6A703A7FF33EQ38940588-8623FD56-4534-4266-A169-74E6D918E030Q42205484-7E1620FB-0B99-4B48-88EA-518ACEE27272Q49991976-3BD8ED8E-AEB6-4646-A283-EAB665D3340DQ53621686-351221F3-EE33-4216-A236-E85EB52568DFQ55019724-C5D31EE6-4983-4E47-9DBF-675422B1B29D
P2860
Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker.
description
2008 nî lūn-bûn
@nan
2008 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Modified FOLFOX-6 chemotherapy ...... dictive and prognostic marker.
@ast
Modified FOLFOX-6 chemotherapy ...... dictive and prognostic marker.
@en
Modified FOLFOX-6 chemotherapy ...... dictive and prognostic marker.
@nl
type
label
Modified FOLFOX-6 chemotherapy ...... dictive and prognostic marker.
@ast
Modified FOLFOX-6 chemotherapy ...... dictive and prognostic marker.
@en
Modified FOLFOX-6 chemotherapy ...... dictive and prognostic marker.
@nl
prefLabel
Modified FOLFOX-6 chemotherapy ...... dictive and prognostic marker.
@ast
Modified FOLFOX-6 chemotherapy ...... dictive and prognostic marker.
@en
Modified FOLFOX-6 chemotherapy ...... dictive and prognostic marker.
@nl
P2093
P2860
P356
P1433
P1476
Modified FOLFOX-6 chemotherapy ...... dictive and prognostic marker.
@en
P2093
Bhumsuk Keam
Dae Seog Heo
Do-Youn Oh
Dong-Wan Kim
Hye Seon Ham
Jee Hyun Kim
Sae-Won Han
Seock-Ah Im
Tae-You Kim
P2860
P2888
P356
10.1186/1471-2407-8-148
P407
P50
P577
2008-05-27T00:00:00Z
P5875
P6179
1004442889